APA (7th ed.) Citation

Marques, P., Domingo, E., Rubio, A., Martinez-Hervás, S., Ascaso, J. F., Piqueras, L., . . . Sanz, M. (2022). Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Elsevier.

Chicago Style (17th ed.) Citation

Marques, Patrice, Elena Domingo, Arantxa Rubio, Sergio Martinez-Hervás, Juan F. Ascaso, Laura Piqueras, José T. Real, and Maria-Jesus Sanz. Beneficial Effects of PCSK9 Inhibition with Alirocumab in Familial Hypercholesterolemia Involve Modulation of New Immune Players. Elsevier, 2022.

MLA (8th ed.) Citation

Marques, Patrice, et al. Beneficial Effects of PCSK9 Inhibition with Alirocumab in Familial Hypercholesterolemia Involve Modulation of New Immune Players. Elsevier, 2022.